Predicting event times in clinical trials when treatment arm is masked

Journal of Biopharmaceutical Statistics

Volumn 16, Issue 3, 2006, Pages 343-356

  Donovan, J Mark ^a,b   Elliott, Michael R ^c   Heitjan, Daniel F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 206 Carnegie Center   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bayesian prediction; Clinical trials; Survival analysis

Indexed keywords

ANTIBIOTIC AGENT; GAMMA INTERFERON; PLACEBO;

ACCURACY; ANTIBIOTIC THERAPY; ARTICLE; BAYES THEOREM; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; DATA ANALYSIS; FOLLOW UP; HOSPITALIZATION; HUMAN; OUTCOME ASSESSMENT; PARAMETRIC TEST; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECURRENT INFECTION; SAMPLE SIZE; SIMULATION; SURVIVAL;

BAYES THEOREM; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; INTERFERON TYPE II; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 33646231035     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400600609445     Document Type: Article

References (14)

1. Al-Hussaini, E. K. (2003). Bayesian predictive density of order statistics based on finite mixture models. J. Stat. Plann. Infer. 113:15-24.
2. Bagiella, E., Heitjan, D. F. (2001). Predicting analysis times in randomized clinical trials. Stat. Med. 20:2055-2063.
3. Fleming, T. R., Harrington, D. P. (1991). Counting Processes and Survival Analysis. New York: Wiley.
4. Gelman, A., Carlin, J. B., Stern, H. S., Rubin, D. B. (1995). Bayesian Data Analysis. Boca Raton: Chapman and Hall.
5. Gould, A. L., Shih, W. J. (1992). Sample size re-estimation without unblinding for normality distributed outcomes with known variance. Commun. Stat. Theory Methods 21:2833-2853.
6. Gould, A. L., Shih, W. J. (1998). Modifying the design of ongoing trials without unblinding. Stat. Med. 17:89-100.
7. International Chronic Granulomatous Disease Cooperative Study Group. (1991). A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 324:509-516.
8. Lachin, J. M., Foulkes, M. A. (1986). Evaluation of sample size and power for analysis of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42:507-519.
9. McLachlin, G., Peel, D. (2000). Finite Mixture Models. New York: Wiley.
10. Proschan, M. A., Follmann, D. A., Waclawiw, M. A. (1992). Effects of assumption violations on type I error rate in group sequential monitoring. Biometrics 48:1131-1143.
11. Rubinstein, L. V., Gail, M. H., Santner, T. J. (1981). Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J. Chron. Dis. 34:469-479.
12. Schoenfeld, D. A. (1983). Sample-size formula for the proportional hazards regression model. Biometrics 39:499-503.
13. Ying, G. S. (2004). Prediction of Event Times in Randomized Clinical Trials. Doctoral Dissertation, Philadelphia, PA: University of Pennsylvania.
14. Ying, G. S., Heitjan, D. F., Chen, T. T. (2004). Nonparametric prediction of event times in randomized clinical trials. Clin. Trials 1:352-361.